NexTurnBio Subsidiary Rosvivo Reports Blood Sugar Level Reduction via Subcutaneous Injection

[Asia Economy Reporter Jang Hyowon] Nexten Bio announced on the 12th that its subsidiary RosVivo Therapeutics (hereinafter RosVivo) confirmed the diabetes treatment effect of the pipeline ‘RSVI-301,’ which is being developed as a diabetes treatment, through subcutaneous injection administration.

RosVivo experimented with two administration methods for RSVI-301: intraperitoneal injection and subcutaneous injection. RSVI-301 administered via subcutaneous injection showed effective blood sugar reduction results similar to those of rats injected intraperitoneally.

Through this preclinical trial result, RosVivo confirmed the possibility of developing a subcutaneous injection that allows patients to easily self-administer the drug, and plans to accelerate clinical development as a diabetes treatment candidate in the future.

Subcutaneous injection is the most commonly used administration method in the human body. Currently marketed diabetes treatments, such as GLP-1 receptor agonists (liraglutide), use subcutaneous injections. The advantage is that the drug is absorbed relatively slowly in the body, allowing for a long-lasting effect.

A Nexten Bio official said, “Through this experimental result, we expect that diabetes patients will be able to minimize inconvenience in treatment by using the easy method of subcutaneous injection,” and added, “Not only the subcutaneous injection method but also the extended dosing cycle of twice every six months is expected to contribute to improving patients’ quality of life.”

He continued, “Nexten Bio’s success in knocking on the door to the world’s first curative treatment for diabetes and solidifying its position as a diabetes treatment company makes this experimental result even more meaningful.”

Meanwhile, RosVivo is negotiating technology export agreements with global pharmaceutical companies such as Eli Lilly, Novo Nordisk, and China’s Tonghua Dongbao Pharmaceutical through the development of diabetes treatments with new mechanisms different from existing treatments, and is receiving invitation inquiries from prestigious international academic conferences.